Eric Van Cutsem

发表

Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.

Sabine Tejpar, Volker Heinemann, Frank Beier, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

Sabine Tejpar, Mauro Delorenzi, Dirk Klingbiel, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.

E. Van Cutsem, H. Lenz, Z. Tsuchihashi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

Armando Santoro, David Khayat, David Cunningham, 2004, The New England journal of medicine.

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Naotoshi Sugimoto, Yasuhiro Shimada, David Ferry, 2014, The Lancet. Oncology.

Towards a pan-European consensus on the treatment of patients with colorectal liver metastases.

M. Ychou, E. Van Cutsem, B. Nordlinger, 2006, European journal of cancer.

Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer

Yasuo Ohashi, Junichi Sakamoto, Tomasz Burzykowski, 2009 .

Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery

Sabine Tejpar, Levi Garraway, Andrea Bild, 2010, The oncologist.

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

Thomas Gruenberger, Laurence Collette, Peter M Schlag, 2008, The Lancet.

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

David Goldstein, Manuel Hidalgo, Thomas Ervin, 2013, The New England journal of medicine.

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

Gary Middleton, Takayuki Yoshino, Chloe E Atreya, 2018, Cancer discovery.

Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

Marc Peeters, Yasuhiro Shimada, Ben Tran, 2015, The New England journal of medicine.

Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study.

Murielle Mauer, Marc Peeters, Ulrich T Hacker, 2018, European journal of cancer.

Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth.

Frederik Nevens, E. Van Cutsem, F. Nevens, 2013, Cancer letters.

Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis.

Satoshi Morita, Yasuo Ohashi, Junichi Sakamoto, 2013, European journal of cancer.

Stool Tagging Applied in Thin-slice Multidetector Computed Tomography Colonography

Hilde Bosmans, Guy Marchal, Gabriel Kiss, 2003, Journal of computer assisted tomography.

EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum.

Karin Haustermans, Cornelis J H van de Velde, Vincenzo Valentini, 2014, European journal of cancer.

Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.

Satoshi Morita, Yasuo Ohashi, Junichi Sakamoto, 2013, Journal of the National Cancer Institute.

Predicting the tumor response to chemoradiotherapy for rectal cancer: Model development and external validation using MRI radiomics.

Olivier Gevaert, Philippe Bulens, Karin Haustermans, 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Marc Peeters, Bart Neyns, E. Van Cutsem, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results.

Karin Haustermans, Vincent Vandecaveye, Frederik De Keyzer, 2012, International journal of radiation oncology, biology, physics.

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.

Harpreet Wasan, Takayuki Yoshino, Josep Tabernero, 2019, The New England journal of medicine.

Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.

Jan Fagerberg, René Bruno, Pascal Girard, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.

Daniel J Sargent, Greg Yothers, Qian Shi, 2013, Clinical colorectal cancer.

Epidermal Growth Factor Receptor Activity Determines Response of Colorectal Cancer Cells to Gefitinib Alone and in Combination with Chemotherapy

Sandra Van Schaeybroeck, Daniel Longley, D. Longley, 2005, Clinical Cancer Research.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Sabine Tejpar, Federico Cappuzzo, Mauro Delorenzi, 2010, The Lancet. Oncology.

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.

Daniel J Sargent, Christophe Tournigand, Eduardo Diaz-Rubio, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

Marc Peeters, Hua Yu, Gregory Wilson, 2015, Clinical Cancer Research.

Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma?

Karin Haustermans, Nadine Ectors, Walter De Wever, 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.

Rodrigo Dienstmann, Josep Tabernero, B. Tops, 2015, Cancer discovery.

Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer.

Sabine Tejpar, Eva Budinska, Graeme Hodgson, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Unmet needs and challenges in gastric cancer: the way forward.

Fátima Carneiro, Josep Tabernero, William Allum, 2014, Cancer treatment reviews.